EA201991336A1 - METHODS FOR TREATING CANCER USING AN ANTIBODIES TO PD-1 - Google Patents

METHODS FOR TREATING CANCER USING AN ANTIBODIES TO PD-1

Info

Publication number
EA201991336A1
EA201991336A1 EA201991336A EA201991336A EA201991336A1 EA 201991336 A1 EA201991336 A1 EA 201991336A1 EA 201991336 A EA201991336 A EA 201991336A EA 201991336 A EA201991336 A EA 201991336A EA 201991336 A1 EA201991336 A1 EA 201991336A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
methods
treating cancer
cancer
patients
Prior art date
Application number
EA201991336A
Other languages
Russian (ru)
Inventor
Дэвид Дженкинс
Хэйли Лэйкен
Элли Им
Аллен Диаз
Шэрон Лу
Original Assignee
Тесаро, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тесаро, Инк. filed Critical Тесаро, Инк.
Priority claimed from PCT/US2018/013029 external-priority patent/WO2018129559A1/en
Publication of EA201991336A1 publication Critical patent/EA201991336A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

В настоящем изобретении предусмотрены способы введения определенных связывающих PD-1 средств пациентам, имеющим рак. Также подробно представлены схемы введения доз для композиций, содержащих связывающее PD-1 средство.The present invention provides methods for administering certain PD-1 binding agents to patients having cancer. Dosage regimens for compositions containing a PD-1 binding agent are also presented in detail.

EA201991336A 2017-09-09 2018-01-09 METHODS FOR TREATING CANCER USING AN ANTIBODIES TO PD-1 EA201991336A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762556386P 2017-09-09 2017-09-09
PCT/US2018/013029 WO2018129559A1 (en) 2017-01-09 2018-01-09 Methods of treating cancer with anti-pd-1 antibodies

Publications (1)

Publication Number Publication Date
EA201991336A1 true EA201991336A1 (en) 2020-01-09

Family

ID=69374484

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991336A EA201991336A1 (en) 2017-09-09 2018-01-09 METHODS FOR TREATING CANCER USING AN ANTIBODIES TO PD-1

Country Status (1)

Country Link
EA (1) EA201991336A1 (en)

Similar Documents

Publication Publication Date Title
MX2019008208A (en) Methods of treating cancer with anti-tim-3 antibodies.
MX2019008207A (en) Methods of treating cancer with anti-pd-1 antibodies.
CY1124791T1 (en) CD73-SPECIFIC BINDING MOLECULES AND USES THEREOF
CY1122984T1 (en) CARBAMIDE COMPOUNDS AND METHODS OF THEIR PREPARATION AND USE
EA201790674A1 (en) CYTOTOXIC INDUCING THERAPEUTIC AGENT
PH12019501663A1 (en) Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
EA201891983A1 (en) COMBINED THERAPY WITH ANTIBODIES TO CD73
EA201692285A8 (en) EZH2 INHIBITORS FOR TREATING LYMPHOMA
MX2019001517A (en) Modified antibody-albumin nanoparticle complexes for cancer treatment.
EA201692530A1 (en) CYTOTOXIC PEPTIDES AND THEIR CONJUGATES
MX2016009717A (en) Bifunctional cytotoxic agents.
GEP20217271B (en) Combination therapy for the treatment of cancer
MX2019008028A (en) Anti-folr1 immunoconjugate dosing regimens.
MX2018011054A (en) Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody.
MX2021009222A (en) Anti-folr1 immunoconjugate dosing regimens.
EA202090098A1 (en) PHARMACEUTICAL COMPOSITIONS OF THERAPEUTICALLY ACTIVE COMPOUNDS
EA201791203A1 (en) DRUG ANTIBODY AGAINST c-MET
EA201692481A1 (en) COMBINATION CONTAINING GLUCOCORTICOID AND EDO-S101
EA201791227A1 (en) DOSING MODE OF MAdCAM ANTAGONISTS
EA201890898A1 (en) NEW CONNECTIONS AND CRYPTOPHICINE CONJUGATES, THEIR RECOVERY AND THEIR THERAPEUTIC APPLICATION
MY186711A (en) Igf-1r antibody-drug-conjugate and its use for the treatment of cancer
MX2016016419A (en) Texaphyrin-pt(iv) conjugates and compositions for use in overcoming platinum resistance.
BR112017011538A2 (en) combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma)
MX2018014129A (en) Pharmaceutical composition comprising eteplirsen.